FDA to Review High-Concentration Biosimilar of Adalimumab
The FDA has accepted for review the BLA for AVT02 (Alvotech), a proposed biosimilar to adalimumab; AbbVie, with high concentration (100mg/mL) dosage forms.
The FDA has accepted for review the BLA for AVT02 (Alvotech), a proposed biosimilar to adalimumab; AbbVie, with high concentration (100mg/mL) dosage forms.
An overview of the risk for infections during targeted and biologic therapies in rheumatoid arthritis and psoriatic arthritis.
The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.
Researchers evaluated the safety and efficacy of tofacitinib for the treatment of patients with ankylosing spondylitis.
Study authors reported on the 1-year safety and efficacy of guselkumab treatment in patients with active psoriatic arthritis.
Researchers assessed the effects of weight loss on disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity.
Study authors evaluated the prevalence of axial spondyloarthritis in patients with inflammatory bowel disease in secondary care.
Researchers assessed whether the gut microbiome in ankylosing spondylitis and inflammatory bowel disease was different, and whether it correlated with disease activity.
Study authors compared the effect of upadacitinib vs placebo and adalimumab on pain in patients with active psoriatic arthritis.
Researchers evaluated the effect of ixekizumab on self-reported functioning and health in patients with active nonradiographic axial spondyloarthritis.